Weir MR, Slee A, Sun T, et al. - Researchers determined if and how canagliflozin (sodium-glucose cotransporter 2 inhibitor) could impact serum potassium levels and hyperkalemia rates in the completed CANagliflozin cardioVascular Assessment Study (CANVAS) Program. It was suggested by pooled analyses of data from early studies and interim data from the CANVAS that canagliflozin might result in rises in serum potassium, especially the 300 mg dose in patients experiencing renal impairment. Two comparable double-blind, randomized, placebo-controlled trials (CANVAS and CANVAS-Renal) were involved in the CANVAS Program (n = 10,142). Participants were administered canagliflozin 100 or 300 mg or placebo. As per findings, serum potassium in the overall population or key subgroups was not meaningfully impacted by canagliflozin in the CANVAS Program. Hyperkalemia adverse events were experienced uncommonly, and these occurred at comparable rates with canagliflozin and placebo.